Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
MWN-AI** Summary
Roche has officially launched the cobas® eplex respiratory pathogen panel 3 (RP3), a diagnostic test that promises to enhance the diagnosis and treatment of respiratory infections. Now available in countries that accept the CE mark, this test is designed to detect a comprehensive range of respiratory pathogens — specifically, it identifies up to 25 different viruses and bacteria from a single patient sample, including notable pathogens like SARS-CoV-2, influenza, Bordetella pertussis, and respiratory syncytial virus (RSV).
The RP3 panel is a part of Roche's cobas eplex system, which offers rapid testing capabilities that are critical in managing high-risk patient populations, such as the elderly, young children, and immunocompromised individuals. Rapid results from this test facilitate timely clinical decisions, allowing healthcare providers to administer targeted treatments and implement infection control measures quickly.
Josh Lauer, Roche Diagnostics’ Global Head of Molecular Labs, emphasized the importance of timely diagnosis in respiratory care, stating, "In respiratory care, time is everything." The cobas eplex RP3 can help reduce unnecessary antibiotic use and improve patient outcomes by enabling swift identification of the specific pathogens involved.
With less than a minute of hands-on time required for test setup, the RP3 panel ensures efficiency for laboratory staff while improving workflow. This versatility is especially crucial during peak respiratory seasons, which often burden healthcare facilities. Additionally, the RP3 panel includes new capabilities for syndromic testing, allowing laboratories to customize panels based on local epidemiological data.
Overall, the launch of the cobas eplex RP3 marks a significant advancement in diagnostics, equipping clinicians with a powerful tool to combat respiratory infections effectively.
MWN-AI** Analysis
Roche's recent launch of the cobas eplex respiratory pathogen panel 3 (RP3) represents a significant advancement in diagnostic testing for respiratory infections, particularly in the CE markets. This innovative test, capable of detecting up to 250 viruses and bacteria, including prevalent pathogens like SARS-CoV-2 and influenza, offers clinicians a crucial tool for timely and accurate diagnosis.
From a market perspective, Roche's RP3 panel is poised to address unmet needs within healthcare systems, particularly as respiratory illness spikes during peak seasons. By enabling rapid results and simplifying the diagnostic process with less than one minute of hands-on time, this test not only enhances patient care but also optimizes hospital resources. It is especially beneficial for high-risk populations, which underscores the growing focus on personalized and targeted healthcare solutions.
Investors should consider several key factors regarding Roche's market positioning. First, the healthcare landscape is increasingly leaning towards efficient, cost-effective diagnostics, especially in infectious disease management—a sector that has seen heightened attention post-COVID-19. Roche’s emphasis on rapid and accurate diagnostics aligns well with this trend, likely enhancing its competitive edge against rivals that may not offer comparable technologies.
Moreover, the ability to customize testing panels based on local prevalence enhances the RP3 panel's adaptability, catering to diverse healthcare environments. This flexibility could lead to increased adoption rates across various hospital settings, positively impacting Roche's revenue streams.
In summary, Roche’s launch of the cobas eplex RP3 is a strategic move that not only reinforces its leadership in molecular diagnostics but also positions the company favorably for growth in an evolving healthcare market. Investors should keep a close watch on Roche’s performance and market uptake of the RP3 panel, as it may yield significant returns in the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample.
- Rapid results enable doctors to make fast, confident and critical treatment decisions that are vital for high-risk patients.
- Designed for the cobas eplex system, the test is easy to use and available around the clock, helping hospitals manage surges in respiratory cases.
PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spectrum of viruses and bacteria that cause respiratory illness. The test is now available in countries accepting the CE mark.
Differential diagnosis of respiratory infections can be complex because many of the viruses and bacteria associated with respiratory infections may cause very similar symptoms. For vulnerable populations, including the elderly, young children, and those with weakened immune systems, a respiratory infection can quickly become life-threatening.
"In respiratory care, time is everything. Knowing exactly what is making a patient sick allows clinicians to make fast, effective decisions that can save lives," said Josh Lauer, Global Head of Molecular Labs at Roche Diagnostics. "We are providing hospitals with a powerful tool to manage the complexity of respiratory infections, ensuring that patients — especially those at high risk — get the targeted care they need without delay."
The cobas eplex RP3 panel provides critical support to healthcare providers during peak respiratory seasons, which are the most demanding times of the year. The new test detects more than 20 different viral and bacterial pathogens simultaneously. This helps clinicians quickly pinpoint the exact cause of a patient's illness, allowing them to start the right treatment sooner, implement adequate infection and transmission control measures, and, in some cases, avoid unnecessary antibiotic use and improve patient prognosis.
With less than one minute of hands-on time required to start the test, it is incredibly easy for laboratory staff to use. With ease of use and fast time to results, the cobas eplex RP3 panel can help reduce the time patients spend in the emergency room and allows hospitals to better manage isolation beds, keeping infectious patients separate from others.
About the cobas eplex RP3 Panel
The cobas eplex respiratory pathogen panel 3 is a qualitative in vitro diagnostic test aimed at the simultaneous detection and differentiation of up to 25 viral and bacterial targets. It runs on the cobas eplex system, a platform designed to simplify laboratory workflow with features like automated result reporting and external control tracking & monitoring. Like the RP2 panel, the RP3 panel detects common pathogens, such as influenza virus A and B, RSV, SARS-CoV-2,, plus new pathogens including Bordetella parapertussis and Chlamydia pneumoniae that can cause severe illness in high risk patients. The cobas eplex RP3 panel also has updated inclusivity for influenza virus and SARS-CoV-2 to ensure coverage of current and recently circulating strains. This test is also the first in the cobas eplex family to feature flexible syndromic testing, giving the option to labs to customise up to 5 distinct panels based on local prevalence needs or unique patient presentations.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact
Yvette Petillon, Group Media Relations
Phone: +41 79 961 92 50
e-Mail: yvette.petillon@roche.com
Brien Mahoney, Molecular Labs Communications
Phone: +1 925 699 8512
e-Mail: brien.mahoney@roche.com
SOURCE Roche
FAQ**
How does the launch of the cobas eplex respiratory pathogen panel 3 position Roche Holding Ltd ADR RHHBY in the competitive landscape of diagnostics for respiratory infections in CE markets?
What specific improvements in patient outcomes can clinicians expect from using the cobas eplex RP3 panel developed by Roche Holding Ltd ADR RHHBY?
How does Roche Holding Ltd ADR RHHBY plan to promote the accessibility and adoption of the cobas eplex RP3 panel among healthcare providers, especially during peak respiratory seasons?
What strategies are in place for Roche Holding Ltd ADR RHHBY to ensure the cobas eplex RP3 panel remains updated with current and emerging respiratory pathogens in the market?
**MWN-AI FAQ is based on asking OpenAI questions about Roche Holding Ltd ADR (OTC: RHHBY).
NASDAQ: RHHBY
RHHBY Trading
-0.24% G/L:
$49.23 Last:
583,766 Volume:
$48.91 Open:
